Physician profile
Li-Ching Chen
NPI 1578577326
$836.71
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $116.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $210.12 | 2019 | |
| Novo Nordisk INC | $176.53 | 2019-2020 | |
| Sobi, INC | $102.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $90.50 | 2019-2020 | |
| Amgen INC. | $78.31 | 2019 | |
| Glaxosmithkline, LLC. | $70.26 | 2019 | |
| Boston Scientific Corporation | $33.22 | 2019 | |
| Aspira Women'S Health INC | $25.90 | 2020 | |
| Therapeuticsmd, INC. | $24.63 | 2019 | |
| Hologic Sales and Service, LLC | $13.16 | 2020 | |
| Genentech USA, INC. | $11.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li-Ching Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.